1. Home
  2. NMRA vs NTHI Comparison

NMRA vs NTHI Comparison

Compare NMRA & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMRA
  • NTHI
  • Stock Information
  • Founded
  • NMRA 2019
  • NTHI 2008
  • Country
  • NMRA United States
  • NTHI United States
  • Employees
  • NMRA N/A
  • NTHI N/A
  • Industry
  • NMRA
  • NTHI Biotechnology: Pharmaceutical Preparations
  • Sector
  • NMRA
  • NTHI Health Care
  • Exchange
  • NMRA Nasdaq
  • NTHI Nasdaq
  • Market Cap
  • NMRA 268.5M
  • NTHI 229.0M
  • IPO Year
  • NMRA 2023
  • NTHI N/A
  • Fundamental
  • Price
  • NMRA $1.94
  • NTHI $12.09
  • Analyst Decision
  • NMRA Hold
  • NTHI
  • Analyst Count
  • NMRA 8
  • NTHI 0
  • Target Price
  • NMRA $5.83
  • NTHI N/A
  • AVG Volume (30 Days)
  • NMRA 506.9K
  • NTHI 129.9K
  • Earning Date
  • NMRA 11-11-2025
  • NTHI 11-19-2025
  • Dividend Yield
  • NMRA N/A
  • NTHI N/A
  • EPS Growth
  • NMRA N/A
  • NTHI N/A
  • EPS
  • NMRA N/A
  • NTHI N/A
  • Revenue
  • NMRA N/A
  • NTHI $59,990.00
  • Revenue This Year
  • NMRA N/A
  • NTHI N/A
  • Revenue Next Year
  • NMRA N/A
  • NTHI N/A
  • P/E Ratio
  • NMRA N/A
  • NTHI N/A
  • Revenue Growth
  • NMRA N/A
  • NTHI N/A
  • 52 Week Low
  • NMRA $0.61
  • NTHI $3.20
  • 52 Week High
  • NMRA $17.19
  • NTHI $25.00
  • Technical
  • Relative Strength Index (RSI)
  • NMRA 58.78
  • NTHI N/A
  • Support Level
  • NMRA $1.70
  • NTHI N/A
  • Resistance Level
  • NMRA $1.93
  • NTHI N/A
  • Average True Range (ATR)
  • NMRA 0.13
  • NTHI 0.00
  • MACD
  • NMRA 0.01
  • NTHI 0.00
  • Stochastic Oscillator
  • NMRA 82.05
  • NTHI 0.00

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

About NTHI NeOnc Technologies Holdings Inc. Common Stock

NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).

Share on Social Networks: